Cell Biology Unit

>>>Cell Biology Unit

The Cell Biology Unit (UBC) is a technology-based platform whose mission is to offer advice and support to several research groups or industries in different projects that use cell cultures and flow cytometry as a main technology. Since 2007, our unit carries out collaborative actions with the Servicio de Clasificación Celular y Citometría de Flujo (SECIF) from Clemente Estable Institute.

Using these technologies (cell culture and flow cytometry) we develop research projects in the area of biotechnology.

The UBC is also member of the Molecular, Cellular and Animal Technology Program (ProTeMCA), one of the institutionally supported programs.


PhD Romina Pagotto

Associate researcher

pagotto@pasteur.edu.uy


PhD Cecilia Abreu

Associate researcher

abreu@pasteur.edu.uy


PhD Vanesa Piattoni

Associate researcher, PosDoc

cvpiattoni@pasteur.edu.uy


MSc Karen Perelmuter

Associate Technician

kperelmuter@pasteur.edu.uy


María Paula Céspedes

Associate Technician, MSc student

pcespedes@pasteur.edu.uy


PhD Tatiana Basika

Assistant Technician

tbasika@pasteur.edu.uy


MSc Hellen Daghero

Research assistant

hdaghero@pasteur.edu.uy


Karin Grunberg

Assistant Technician, MSC student

kgrunberg@pasteur.edu.uy


Constanza Silvera

Assistant Technician, undergraduate student

csilvera@pasteur.edu.uy

  • CELL TECHNOLOGY:
    Our group has been dedicated to the generation and characterization of recombinant cell lines of biomedicine and biotechnological interest. Among them, we use a great variety of reporter cell lines (IFN type I, NF-kB, redox biosensors, among others) to search for and characterize substances that interfere with the signaling pathways of type I IFNs (Burgi et al, 2012 and Burgi et al, 2016). Also we use them in in-vitro models of inflammation (NF-kB, Tiscornia et al, 2012 Mastropietro et al, 2015; Rolny et al, 2016) or to improve the metabolism/productivity of cells of biotechnological interest (redox biosensors within the framework of ProTeMCA).

  • ENVIRONMENTAL TOXICOLOGY:
    Endocrine disruptors (ED) are anthropogenic substances present in the environment, capable of altering the homeostasis of the endocrine system of
    organisms, contributing to the development of pathologies. Our working hypothesis is that the increase of certain reproductive pathologies is caused, in part, by the increasing exposure to EDs present in the environment. In this context, we have validated an in vivo model —the transgenic mouse Oct4-GFP— for toxicological monitoring of environmental estrogens (Porro et al, 2015). We have also developed an in vitro assay that uses a dual reporter cell line and allows us to evaluate in a single test the estrogenic or androgenic activity of a putative ED. In this line of research, we are collaborating with Dr. Rodríguez (ISAL, CONICET-UNL, Argentina).

  • ANTITUMORAL PEPTIDES:
    Since 2011, we have collaborated with Dr. Vallespi, from the Center for Genetic Engineering and Biotechnology (CIGB), in Cuba, on the project “CIGB-552: novel peptide with antitumor and anti-inflammatory properties useful for cancer treatment”.
    We demonstrate that CIGB-552 is effective in reducing the size of tumours present in mice and we identify the COMMD1 protein as a key mediator for its antitumor activity (Fernández Massó et al, 2013, Vallespí et al., 2014, Núñez de Villavicencio et al., 2015).
    Recently, we described the minimum functional unit of CIGB-552 necessary to exercise its biological activity (ability to penetrate tumor cells, interact with COMMD1 and induce apoptosis, Astrada et al, 2016 and 2018).

  • TISSUE ENGINEERING: INTESTINAL ORGANOIDS AND 3D CROPS:
    Traditional cell cultures, in two dimensions, offer a simple, rapid, economic and reproducible evaluation system. However, they lack the ability to recreate the cellular interactions that take place in a tissue in vivo, limiting its predictive power. Our goal is to generate and characterize cellular models in three dimensions (3D) that resemble living systems, improving the correlation of results. In particular, we propose to establish a murine intestinal organoid culture, either from primary tissue or by differentiation of induced pluripotent stem cells (from the English iPSC) and apply them in the study of inflammation, cancer and probiotic screening.

LABORATORY OF CELLULAR CROPS

  • We have several laboratories equipped to work in an aseptic environment, such as biological safety cabinets, CO2incubators, cytological centrifuges and inverted microscopes.
    We also have an Automatic Analyzer for Glucose and Lactate Bioprofile Basic 2 Analyzer  (Nova Biomedical)

FLOW CYTOMETRY LABORATORY

Cellular analyzers:

  • Latin American School of Flow Cytometry. October 1-5, 2018. Institut Pasteur de Montevideo and Faculty of Medicine, Uruguay. Funded by ANII, IPMontevideo, GRCF, ISAC, Udelar, PEDECIBA, ProInBio. Course coordinators: Bollati M, Lens, Giordano,Blanco, Malusardi.

  • Course “Alternative Methods to Lab Animals use”.May 21-25, 2018. Institut Pasteur de Montevideo, Uruguay. Funded by IPMontevideo, Premasur, LÓreal. Course coordinators: Bollati M, Crispo M, De Vecchi R.

  • International Course “Cell and Animal Models for Drug Discovery”. October 16 to 27, 2017. Institut Pasteur de Montevideo. Funded by ICGEB, RIIP, UNU BIOLAC, ESACT and FOCEM. Course coordinators: Bollati M, Crispo M, Comini M, Alves P.

  • Basic course in flow cytometry and its applications in research. February 22-26, 2016. Institut Pasteur de Montevideo, IIBCE, Uruguay. Funded by PEDECIBA. Coordinators of the course: Victoria S, Perelmuter K, Bollati M.

  • International course  “Flow cytometry and cell sorting in biotechnology and biomedicine research”. April 17-28, 2014. Institut Pasteur de Montevideo. Funded by RIIP, ICGEB, UNU-Biolac and TWAS. Course coordinators: Bollati M, Gröbe L, García JM.

  • Course “Fundamentals and applications of flow cytometry”. October 7-18, 2013, Institut Pasteur de Montevideo, IIBCE, Uruguay. Sponsored by PEDECIBA and ProInBio.Course coordinators: Folle G, Porro V and Bollati M.

  • IV Latin American Seminar on Cellular Technology. November 7-9, 2010 – Hotel Ermitage, Montevideo. Funded by ICGEB, UNU-Biolac. Organizing Committee: Bollati M, Kratje R.

  • International course “Animal Cell Biotechnology: Product from cells, cells as product”, November 10-19, 2010, Institut Pasteur de Montevideo, Uruguay. Funded by ICGEB, UNU-Biolac. Organizing Committee: Bollati M, Kratje R.

  • International Course. MidTerm HEVAR Conference on Viral vectors as genetic vaccines against pathogens. April 7-13, 2008, University of the Republic – Institut Pasteur of Montevideo, Uruguay. Organizing Committee: Arbiza J, Epstein A, Fraefel C, Glikmann G, Bollati M.

  • 2019-2021 – New molecular tools for reducing production costs of bioactive molecules. FMV_3_2018_1_148443. Responsible: Cecilia Abreu. Member of the research team: Mariela Bollati.

  • 2019-2021 – Generation of polyphenol-rich extracts from grape pomaces. Alliance for Innovation – ANII ALI_2_2018_1_149574. Responsible: Margot Paulino. Member of the research team: Mariela Bollati.

  • 2019-2020 – Cannabis and autism: characterization, extraction and effects in animal and cellular models. ALI_1_2018_1_147904. Responsible: Inés Carrera. Member of the research team: Mariela Bollati.

  • 2018-2020 – Mitochondrial bioenergetics in senescence induced by melanoma therapy: assessing the impact on tumor development. FCE_1_2017_1_136021. Responsible: Celia Quijano. Consultant: Mariela Bollati.

  • 2018-2019 – In silico approach for the identification and evaluation of mechanisms of action of bioactive peptides from different food sources. FSDA_1_2017_1_143964. Responsible: Margot Paulino. Member of the research team: Mariela Bollati.

  • 2016-2018 – Generation and characterization of in vitro models for the study of endocrine disruptors. Responsible: M. Bollati. MOV_CO_2015_1_110054

  • 2015-2018 – Design of biosensors for simultaneous monitoring of redox signalingand cAMP: From the computer to the cell and back to the computer. Responsible: S. Pantano. FMV_1_2014_1_104000

  • 2014-2015 – High speed, multiparametric and biosecure cellular separator for biomedicine and biotechnological use. National Agency for Research and Innovation, ANII (EQC_2013_X_1_2, Uruguay). Principal Investigator: Mariela Bollati-Fogolin.

  • 2013-2015 – Risk assessment for exposure to anthropogenic environmental estrogens in a model of transgenic mice Oct-4-GFP. National Agency for Research and Innovation, ANII. María Viñas Fund PR_ FMV_2_ 2011_1_6046 (Uruguay). Principal Investigator: Mariela Bollati-Fogolin

  • 2012-2013 – Monitoring of natural and synthetic compounds that modulate the biological activity of type I interferons using a new reporter gene assay. Bilateral international cooperation Uruguay-Argentina (DICyT and MEC), Researchers Responsible: Mariela Bollati-Fogolín (Uruguay), Marcos Oggero (Argentina)

Relationship with the productive sector

The UBC has been working with the following companies by provision a particular
service, on a technological development contract, and as a consultant:

  • Mega Pharma (Uruguay): 2018

  • Biogénesis Bagó (Argentina): 2015-2019

  • BIOPOLIS (España), 2009-2013.

  • MICROSULES Laboratories (Uruguay), 2012-2013.

  • GRANUY (GRANAR GROUP, Paraguay – Uruguay), 2012-2013.

  • VIRBAC GROUP (France), 2011.

  • Laboratories SANTA ELENA SA (Uruguay), 2010–2011.

  • DANONE Research (France), 2007-2009.

  • CLAUSEN Laboratories(Uruguay), 2007–2018.

  • Bürgi M, Hernández P, Cabrera M, Cerecetto H, González M, Kratje R, Raimondi A, Oggero M, Bollati-Fogolín M. Identification and characterization of human interferon alpha antagonist compounds through a wish cell line based reporter gene assay. M. Bioorganic Chemistry doi.org/10.1016/j.bioorg.2019.103372.

  • Martínez J, Tarallo D, Martínez-Palma L, Victoria S, Bresque M, Rodriguez-Bottero S, Marmisolle I, Escande C, Cassina P, Casanova G, Bollati-Fogolín M, Agorio C, Moreno M, Quijano C. Mitofusins modulate the increase in mitochondrial length, bioenergetics and secretory phenotype in therapy-induced senescent melanoma cells. Biochem J. 2019 Sep 10;476(17):2463-2486. doi: 10.1042/BCJ20190405.

  • Daghero H, Pagotto R, Vallespí M, Bollati-Fogolín M. Generation of stable reporter breast and lung cancer cell lines for NF-kB activation studies. J Biotechnol. 2019 May 27. pii: S0168-1656(19)30178-6. doi: 10.1016/j.jbiotec.2019.05.014.

  • Piattoni CV, Sardi F, Klein F, Pantano S, Bollati-Fogolín M, Comini M. New red-shifted fluorescent biosensor for monitoring intracellular redox changes. Free Radic Biol Med. 2019 Feb 5;134:545-554. doi: 10.1016/j.freeradbiomed.2019.01.035.

  • Astrada S, Fernández Massó JR, Vallespí MG, Bollati-Fogolín M. 2018. Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity. Molecules Mar 30;23(4).

  • Ingold M, Dapueto R, Victoria S, Galliusi G, Batthyàny C, Bollati-Fogolín M, Tejedor D, García-Tellado F, Padrón JM, Porcal W, López GV. 2018. A green multicomponent synthesis of tocopherol analogues with antiproliferative activities. Eur J Med Chem. 2018 Jan 1;143:1888-1902.

  • Schroeder M.E., Russo S., Costa C., Hori J., Tiscornia I., Bollati-Fogolín M., Zamboni D.S., Ferreira G., Cairoli E., Hill M. 2017. Pro-inflammatory Ca++-activated K+ channels are inhibited by hydroxychloroquine. Sci Reo. 2017 May 15;7(1):1892.

  • Mulet AP, Perelmuter K, Bollati-Fogolin M, Crispo M, Grompone G. 2017. Forkhead Box Protein O1 is Linked to Anti-Inflammatory Probiotic Bacteria Acting through Nuclear Factor-κB Pathway. J Microb Biochem Technol Volume 9(3):074-081.

  • Astrada S, Gomez Y, Barrera E, Obal G, Pritsch O, Pantano S, Vallespí MG, Bollati-Fogolín M. Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552. J Pept Sci. 2016 Nov; 22(11-12):711-722. doi: 10.1002/psc.2934.

  • Malacrida L, Astrada S, Briva A, Bollati-Fogolín M, Gratton E, Bagatolli L. Spectral Phasor analysis of LAURDAN fluorescence in live A549 lung cells to study the hydration and time evolution of intracellular lamellar bodies-like structures. Biochim Biophys Acta. 2016 Jul 30. pii: S0005-2736(16)30270-X. doi: 10.1016/j.bbamem.2016.07.017. PMID: 27480804

  • Rolny IS, Tiscornia I, Racedo SM, Pérez PF, Bollati-Fogolín M. Lactobacillus delbrueckii subsp lactis CIDCA 133 modulates response of human epithelial and dendritic cells infected with Bacillus cereus. Benef Microbes. 2016 Jul 26:1-12. PMID: 27459335

  • Bürgi M, Zapol’skii VA, Hinkelmann B, Köster M, Kaufmann DE, Sasse F, Hauser H, Etcheverrigaray M, Kratje R, Bollati-Fogolín M, Oggero M. Screening and characterization of molecules that modulate the biological activity of IFNs-I. J Biotechnol. 2016 Jun 23; 233: 6-16. doi: 10.1016/j.jbiotec.2016.06.021. PMID: 27346232

  • García EP,Tiscornia I, Libisch G, Trajtenberg F, Bollati-Fogolín M, Rodríguez E, Noya V, Chiale C, Brossard N, Robello C, Santiñaque F, Folle G, Osinaga E, Freire T. MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. Int J Oncol. 2016 Mar 10. doi: 10.3892/ijo.2016.3434. PMID: 26984395

  • Ubillos L, Freire T, Berriel E, Chiribao ML, Chiale C, Festari MF, Medeiros A, Mazal D, Rondán M,Bollati-Fogolín M, Rabinovich GA, Robello C, Osinaga E. Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers. Int J Cancer. 2016 Apr 1;138(7):1719-31. doi: 10.1002/ijc.29910. PMID: 26519949

  • Cabrera M, de Ovalle S, Bollati-Fogolín M, Nascimento F, Corbelini P, Janarelli F, Kawano D, Eifler-Lima VL, González M, Cerecetto H. New hits as phase II enzymes inducers from a focused library with heteroatom-heteroatom and Michael-acceptor motives. Future Sci OA. 2015 Nov 1;1(3):FSO20. doi: 10.4155/fso.15.18. eCollection 2015.

  • León IE, Cadavid-Vargas JF, Tiscornia I, Porro V, Castelli S, Katkar P, Desideri A, Bollati-Fogolin M, Etcheverry SB. Oxidovanadium(IV) complexes with chrysin and silibinin: anticancer activity and mechanisms of action in a human colon adenocarcinoma model. J Biol Inorg Chem. 2015 Oct;20(7):1175-91. doi: 10.1007/s00775-015-1298-7.

  • Núñez de Villavicencio-Díaz T, Ramos Gómez Y, Oliva Argüelles B, Fernández Masso JR, Rodríguez-Ulloa A, Cruz García Y, Guirola-Cruz O, Perez-Riverol Y, Javier González L, Tiscornia I, Victoria S, Bollati-Fogolín M, Besada Pérez V, Guerra Vallespi M. Data for comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells. Data Brief. 2015 Jul 8;4:468-73. doi: 10.1016/j.dib.2015.06.024.

  • Porro V, Pagotto R, Harreguy MB, Ramírez S, Crispo M, Santamaría C, Luque EH, Rodríguez HA, Bollati-Fogolín M. Characterization of Oct4-GFP transgenic mice as a model to study the effect of environmental estrogens on the maturation of male germ cells by using flow cytometry. J Steroid Biochem Mol Biol. 2015 Nov;154:53-61. doi: 10.1016/j.jsbmb.2015.06.006.

  • Salzman V, Porro V, Bollati-Fogolín M, Aguilar PS. Quantitation of yeast cell-cell fusion using multicolor flow cytometry. Cytometry A. 2015 Sep;87(9):843-54. doi: 10.1002/cyto.a.22701.

  • Núñez de Villavicencio-Díaz T, Ramos Gómez Y, Oliva Argüelles B, Fernández Masso JR, Rodríguez-Ulloa A, Cruz García Y, Guirola-Cruz O, Perez-Riverol Y, Javier González L, Tiscornia I, Victoria S, Bollati-Fogolín M, Besada Pérez V, Guerra Vallespi M. Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells. J Proteomics. 2015 Aug 3;126:163-71. doi: 10.1016/j.jprot.2015.05.024.

  • Negrotto S, Mena HA, Ure AE, Jaquenod De Giusti C, Bollati-Fogolín M, Vermeulen EM, Schattner M, Gómez RM. Human Plasmacytoid Dendritic Cells Elicited Different Responses after Infection with Pathogenic and Nonpathogenic Junin Virus Strains. J Virol. 2015 Jul;89(14):7409-13. doi: 10.1128/JVI.01014-15. Epub 2015 Apr 29.

  • Mastropietro G, Tiscornia I, Perelmuter K, Astrada S, Bollati-Fogolín M. HT-29 and Caco-2 reporter cell lines for functional studies of nuclear factor kappa B activation. Mediators Inflamm. 2015;2015:860534. doi: 10.1155/2015/860534.

  • Leon IE, Porro V, Di Virgilio AL, Naso LG, Williams PA, Bollati-Fogolín M, Etcheverry SB. Antiproliferative and apoptosis-inducing activity of an oxidovanadium(IV) complex with the flavonoid silibinin against osteosarcoma cells. J Biol Inorg Chem. 2014 Jan;19(1):59-74.

  • Domínguez MF, Koziol U, Porro V, Costábile A, Estrade S, Tort J, Bollati-Fogolin M, Castillo E. A new approach for the characterization of proliferative cells in cestodes. Exp Parasitol. 2014 Mar;138:25-9. doi: 10.1016/j.exppara.2014.01.005

  • Fernández-Calero T, Astrada S, Alberti A, Horjales S, Arnal JF, Rovira C, Bollati-Fogolín M, Flouriot G, Marin M. The transcriptional activities and cellular localization of the human estrogen receptor alpha are affected by the synonymous Ala87 mutation. J Steroid Biochem Mol Biol. 2014 Sep;143:99-104. doi: 10.1016/j.jsbmb.2014.02.016.

  • Beedessee G, Ramanjooloo A, Tiscornia I, Cresteil T, Raghothama S, Arya D, Rao S, Gowd KH, Bollati-Fogolin M, Marie DE. Evaluation of hexane and ethyl acetate extracts of the sponge Jaspis diastra collected from Mauritius Waters on HeLa cells. J Pharm Pharmacol. 2014 Sep;66(9):1317-27. doi: 10.1111/jphp.12256.

  • Vallespí MG, Pimentel G, Cabrales-Rico A, Garza J, Oliva B, Mendoza O, Gomez Y, Basaco T, Sánchez I, Calderón C, Rodriguez JC, Markelova MR, Fichtner I, Astrada S, Bollati-Fogolín M, Garay HE, Reyes O. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models. J Pept Sci. 2014 Jul 20. doi: 10.1002/psc.2676

  • Noya V, Bay S, Festari MF, García E, Rodriguez E, Chiale C, Ganneau C, Baleux F, Astrada S, Bollati–Fogolín M, Osinaga E and Freire T. Mucin-like peptides from Echinococcus granulosus induce antitumor activity. Int J Oncol. 2013 (June 28). DOI: 10.3892/ijo.2013.2000.

  • Chenoll E, Codoñer FM, Silva A, Ibáñez A, Martinez-Blanch JF, Bollati-Fogolín M, Crispo M, Ramírez S, Sanz Y, Ramón D and Genovés S. Genomic Sequence and Pre-Clinical Safety Assessment of Bifidobacterium longum CECT 7347, a Probiotic able to Reduce the Toxicity and Inflammatory Potential of Gliadin-Derived Peptides. J Prob Health 2013, 1: 106. doi: 10.4172/ jph.1000106

  • Leon IE, Di Virgilio AL, Porro V, Muglia CI, Naso LG, Williams PAM, Bollati-Fogolín M and Etcheverry SB. Antitumor properties of a vanadyl(IV) complex with the flavonoid chrysin [VO(chrysin)2EtOH]2 in a human osteosarcoma model: role of the oxidative stress and apoptosis. Dalton Transactions, 2013 (in press).

  • Mazal D, Lo-Man R, Bay S, Pritsch O, Dériaud E, Ganneau C, Medeiros A, Ubillos L, Obal G, Berois N, Bollati-Fogolín M, Leclerc C, Osinaga E. Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer. Cancer Immunol Immunother. 2013 Apr 21. doi: 10.1007/s00262-013-1425-7

  • Fernández Massó JR, Oliva Argüelles B, Tejeda Y, Astrada S, Garay H, Reyes O, Delgado-Roche L, Bollati-Fogolín M, Vallespí MG. The Antitumor Peptide CIGB-552 increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells. J Amino Acids. 2013;2013:251398. doi: 10.1155/2013/251398. Epub 2013 Jan 16.

  • Grompone, G; Martorell, P; Llopis, S; González, N; Genovés, S; Mulet, AP; Fernández-Calero, T; Tiscornia, I; Bollati-Fogolín, M; Chambaud, I; Foligné, B; Montserrat, A; Ramón Vidal, D. Anti-inflammatory Lactobacillus rhamnosus CNCM I-3690 strain protects against oxidative stress and increases lifespan in Caenorhabditis elegans. PLOS ONE 2012;7(12) doi: 10.1371/journal.pone.0052493

  • Tiscornia, I, Sánchez-Martins, V, Hernández, A, Bollati-Fogolín, M. Human monocyte-derived dendritic cells from leukoreduction system chambers after plateletpheresis are functional in an in vitro co-culture assay with intestinal epithelial cells, Journal of Immunological Methods (2012), v: 384 1-2, p:164-170. doi:10.1016/j.jim.2012.07.005

  • Muñoz F, Del Río N, Sóñora C, Tiscornia I, Marco A, Hernández A. Enamel defects associated with coeliac disease: putative role of antibodies against gliadin in pathogenesis. Eur J Oral Sci. 2012 Apr;120(2):104-12. doi: 10.1111/j.1600-0722.2012.00949.x.

  • Bürgi, M.; Prieto, C.; Etcheverrigaray, M.; Kratje, R.; Oggero, M.; Bollati-Fogolín, M. Wish cell line: from the antiviral system to a novel reporter gene assay to test the potency of human IFN-α and IFN-β. Journal of Immunological Methods (2012) Journal of Immunological Methods (2012), 381(1-2):70-4. available online: http://dx.doi.org/10.1016/j.jim.2012.04.010

  • Hernández P., Cabrera M., Lavaggi M.L., Celano L., Tiscornia I., Rodrigues da Costa T., Thomson L., Bollati-Fogolín M., Miranda A.L., Moreira-Lima L., Barreiro E., González M. and Cerecetto H. Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl n-acylhydrazone derivatives. Bioorg Med Chem. 2012; 20(6): 2158-71.

  • Bürgi, M.; Prieto, C.; Oggero, M.; Bollati-Fogolín, M.; Etcheverrigaray, M.; Kratje, R. New reporter cell clones to determine the biological activity of human type I interferons. BMC Proceedings 2011, 5(Suppl 8):P4.

  • Gascue, C; Tan, PL; Cardenas-Rodriguez, M.; Libisch, G.; Fernandez-Calero, T.; Liu, YP; Astrada, S.; Robello, C.; Naya, H; Katsanis, N.; Badano, JL. A Direct Role of Bardet-Biedl Syndrome Proteins in Transcriptional Regulation. Journal of Cell Science. In Press

  • Pils, M; Bleich, A; Fasnacht, N; Bollati-Fogolín, M; Schippers, A; Rozell, B; Müller, W. Commensal gut flora reduces susceptibility to experimentally induced colitis via T-cell derived Interleukin-10. Inflammatory Bowel Diseases 2011 Oct;17(10):2038-46. PMID:21182023

  • Cabrera M, Lavaggi ML, Croce F, Celano L, Thomson L, Fernández M, Pintos C, Raymondo S, Bollati M, Monge A, López de Ceráin A, Piro OE, Cerecetto H, González M. Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers. Bioorganic & Medicinal Chemistry, v. 18 14, p. 5391-5399, 2010. PMID:20639112

  • Palacios F, Moreno P, Morande P, Abreu C, Correa A, Porro V, Landoni AI, Gabus R, Giordano M, Dighiero G, Pritsch O and Oppezzo P. High expression of AID and active Class Switch Recombination accounts for a more aggressive disease in unmutated CLL patients: Link with an activated microenvironment in CLL disease. Blood 2010 Jun 3;115(22):4488-96 PMID:20233972

  • Guimarães FS, Ferrari LA, Martins SH, Sene RV, Wanderer C, Tiscornia I, Bollati-Fogolín M, Trindade ES, de Freitas Buchi D and Abud APR. In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model. BMC Cancer 2010 Mar 25; 10:113 PMID:20338038

  • Madan R, Demircik F, Surianarayanan S, Allen JL, Divanovic S, Trompette A, Yogev N, Gu Y, Khodoun M, Hildeman D, Boespflug N, Fogolin MB, Gröbe L, Greweling M, Finkelman FD, Cardin R, Mohrs M, Müller W, Waisman A, Roers A, Karp CL. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J Immunol. 2009, 183(4):2312-20. PMID:19620304

  • Fasnacht N, Greweling MC, Bollati-Fogolín M, Schippers A, Müller W. T-cell-specific deletion of gp130 renders the highly susceptible IL-10-deficient mouse resistant to intestinal nematode infection. Eur J Immunol. 2009, 39(8):2173-83. PMID:19593768

  • Rodríguez-Casuriaga R, Geisinger A, López-Carro B, Porro V, Wettstein R, Folle GA. Ultra-Fast and Optimized Method for the Preparation of Rodent Testicular Cells for Flow Cytometric Analysis. Biol Proced Online. 2009 Mar 6;11:184-95 PMID:19495915

  • Sudarman E; Bollati-Fogolín M; Hafner M; Mueller W; Scheller J; Rose-John S; Eichler J. Synthetic mimetics of the gp130-binding site for viral Interleukin-6 as inhibitors of the vIL-6 – gp130 interaction. Journal of Peptide Research, 2008, v. 71 5, p. 494-500. PMID:18373551

  • Ceaglio N, Bollati-Fogolín M, Oggero M, Etcheverrigaray M, Kratje R (2014). Chapter 6.2: High cell density cultivation processes. In Animal Cell Biotechnology, Eds Wagner R and Hauser H. De Gruyter. Berlín, Alemania (ISBN 3110278863, 9783110278866), pp. 427 – 454.

  • Bollati-Fogolín, M. and Comini, M. (2008) Clonagem e expressäo de proteinas heterologas em células animais. En: Tecnologia do Cultivo de Céluas Animais: de Biofármacos a Terapia Genica. Castilho, Moraes, Augusto (Eds), Published by Editora Roca Ltda, São Paulo, Brasil, 3: 40-76.

  • Bollati-Fogolín, M. and Comini, M. (2007), Cloning and expression of heterologous proteins in animal cells. En: Animal Cell Technology: From Biopharmaceuticals to Gene Therapy, Castilho, Moraes, Augusto, Butler (Eds), Published by Taylor & Francis Group. 3:39-73.